Empreses emergents
2020
PULMOBIOTICS SLTecnologia per descobrir i desenvolupar nous tractaments i vacunes per a malalties respiratòries Una nova plataforma bioterapèutica en viu per tractar malalties pulmonars humans.
Dades financeres
Propietat CERCA
Barcelona, Spain
2000
Centre de Regulació Genòmica (CRG)
Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
A spin off company from the Centre for Genomic Regulation (Barcelona - Spain) founded by experienced entrepreneurs and funded by invivo Ventures.
Using a proprietary microbial engineering and synthetic biology toolbox our founders have created a platform based on attenuated lung bacteria that is able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.
Pulmobiotics SL will use this technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.
Using a proprietary microbial engineering and synthetic biology toolbox our founders have created a platform based on attenuated lung bacteria that is able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.
Pulmobiotics SL will use this technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.
Descripció del producte
Our platform is based on attenuated lung bacteria able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner. It allows engineering of multiple genetic circuits to specifically target and deliver payloads.
Our VAP product uses attenuated lung bacteria to deliver therapeutic agents with antibacterial activity in the lung in a controlled, local and continuous manner.
This product has already demonstrated activity in vitro and in animal models.
Our VAP product uses attenuated lung bacteria to deliver therapeutic agents with antibacterial activity in the lung in a controlled, local and continuous manner.
This product has already demonstrated activity in vitro and in animal models.